Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Sprout Health vs Remi Meds

Two GLP-1 desks, one scoreboard. We put Sprout Health and Remi Meds head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 6 · Grade B

Sprout Health

Visit Sprout Health Full brief →
vs
No. 379 · Grade C

Remi Meds

Visit Remi Meds Full brief →

The verdict

Sprout Health takes this head-to-head.

Sprout Health scores 86 to 57 on our six-factor Brief Score — A LegitScript-certified desk that pairs low-cost compounded semaglutide and tirzepatide with a real brand-name Wegovy and Zepbound path — and a near-frictionless, often visit-free start.

That doesn't make Remi Meds a bad call — it's best for readers who want per-dose-tier compounded glp-1 with named strive pharmacy partner. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
90
48
Supply Reliability
82
61
Transparency
88
72
Access Breadth
92
50
Clinical Oversight
78
54
Track Record
84
53
Sprout HealthBrief Score 86 · 57Remi Meds

Price, coverage & the tracker

Sprout HealthRemi Meds
Brief Score86/100 (B)57/100 (C)
Semaglutide$149/moFrom $249/mo (0.25 mg dose, compounded)
Tirzepatide$199/moFrom $349/mo (2.25 mg dose, compounded)
CoverageNot disclosedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

Sprout Health: Compounded $149 semaglutide / $199 tirzepatide held flat this cycle, with a brand-name Wegovy/Zepbound path available on the same account.

Remi Meds: New to the tracker on 1 August 2026. The published line reads From $249/mo (0.25 mg dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.